- Primary tumor resection (PTR) was associated with prolonged survival among patients with gastro‐entero‐pancreatic neuroendocrine neoplasms (NEN) with liver metastases.
Why this matters
- PTR should be considered in these patients, but age and primary tumor site, size, and differentiation should be factored into the decision.
- Analysis of the Surveillance, Epidemiology, and End Results database (n=1547), excluding patients who had liver metastases removed.
- Funding: National Natural Science Foundation of China.
- 58.0% underwent PTR.
- Median follow-up, 15 (range, 1-71) months. 42.1% of subjects died.
- PTR was associated with better 5-year OS (57.0% vs 15.4%; P<.001 p in multivariate analysis>
- 5-year OS, PTR vs no PTR, according to primary tumor location (P<.01 for all style="list-style-type:circle;">
- Gastric NEN: 39.7% vs 10.5%.
- Small intestinal NEN: 73.3% vs 29.9%.
- Colorectal NEN: 24.6% vs 4.7%.
- Pancreatic NEN: 59.7% vs 18.1%.
- Age, ≥60 years (HR, 1.58; P<.001>
- Primary site at the small intestine (HR, 0.52; P<.001 or pancreas p=".006).</li">
- Primary tumor size, ≥4 cm (HR, 1.58; P=.007).
- Poor differentiation (HR, 4.48; P<.001 or undifferentiated p>
- Retrospective analysis.